



## Original Article

# Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study



Frank Hullekes<sup>1,2</sup> , Audrey Uffing<sup>1,2</sup> , Rucháma Verhoeff<sup>1,3</sup> , Harald Seeger<sup>4</sup> ,  
Seraina von Moos<sup>4</sup>, Juliana Mansur<sup>5</sup> , Gianna Mastroianni-Kirsztajn<sup>5</sup> ,  
Helio Tedesco Silva<sup>5</sup>, Anna Buxeda<sup>6</sup> , María José Pérez-Sáez<sup>6</sup>,  
Carlos Arias-Cabrales<sup>6</sup> , A. Bernard Collins<sup>7</sup>, Christie Swett<sup>7</sup>, Leela Morená<sup>1</sup> ,  
Marina Loucaidou<sup>8</sup>, Andreas Kousios<sup>8</sup> , Paolo Malvezzi<sup>9</sup> , Mathilde Bugnazet<sup>9</sup>,  
Luis Sanchez Russo<sup>10</sup>, Saif A. Muhsin<sup>11</sup>, Nikhil Agrawal<sup>12</sup>,  
Pitchaphon Nissaisorakarn<sup>12</sup> , Het Patel<sup>12</sup>, Ayman Al Jurdi<sup>1,13</sup> , Enver Akalin<sup>14</sup> ,  
Elias David Neto<sup>15</sup>, Fabiana Agena<sup>15</sup> , Carlucci Ventura<sup>15</sup> , Roberto C. Manfro<sup>16</sup> ,  
Andrea Carla Bauer<sup>16</sup> , Marilda Mazzali<sup>17</sup> , Marcos Vinicius de Sousa<sup>17</sup>,  
Gaetano La Manna<sup>18,19</sup> , Claudia Bini<sup>18,19</sup> , Giorgia Comai<sup>18</sup> ,  
Roman Reindl-Schwaighofer<sup>20</sup> , Stefan Berger<sup>2</sup> , Paolo Cravedi<sup>10</sup> ,  
Leonardo V. Riella<sup>1,13,\*</sup> 

<sup>1</sup> Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>2</sup> Groningen Transplant Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

<sup>3</sup> Department of Surgery, Erasmus Medical Center Transplant Institute, Erasmus University, Rotterdam, The Netherlands

<sup>4</sup> Division of Nephrology, University Hospital Zurich, Zurich, Switzerland

<sup>5</sup> Division of Nephrology, Federal University of Sao Paulo, Sao Paulo, Brazil

<sup>6</sup> Division of Nephrology, Hospital del Mar, Barcelona, Spain

<sup>7</sup> Renal Pathology, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>8</sup> Division of Nephrology, Imperial College London, UK

<sup>9</sup> Department of Nephrology, Dialysis, Apheresis and Transplantation, CHU Grenoble Alpes, Grenoble, France

<sup>10</sup> Translational Transplant Research Center, Renal Division, Icahn School of Medicine at Mount Sinai, New York, New York, USA

<sup>11</sup> Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>12</sup> Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

<sup>13</sup> Department of Medicine, Nephrology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>14</sup> Einstein/Montefiore Transplant Center, Albert Einstein College of Medicine, Bronx, New York, USA

<sup>15</sup> Renal Transplant Service, Division of Nephrology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil

<sup>16</sup> Division of Nephrology, Hospital de clínicas de Porto Alegre/Federal University of Rio Grande do Sul, Porto Alegre, Brazil

<sup>17</sup> Division of Nephrology, School of Medical Sciences, University of Campinas, Campinas, Brazil

Abbreviations: CI, confidence interval; CMV, cytomegalovirus; ELISA, enzyme-linked immunosorbent assay; ESKD, end-stage kidney disease; HR, hazard ratio; IIF, indirect immunofluorescence; IQR, interquartile range; MN, membranous nephropathy; PLA2R, phospholipase A2 receptor; RAAS, renin-angiotensin-aldosterone system; RU, relative unit; TANGO, Post-Transplant Glomerular Disease; THSD7A, thrombospondin type-1 domain containing 7A.

\* Corresponding author. Dr. Leonardo V. Riella, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Boston, MA 02115, USA.

E-mail address: [riella@mgh.harvard.edu](mailto:riella@mgh.harvard.edu) (L.V. Riella).

<https://doi.org/10.1016/j.ajt.2024.01.036>

Received 25 October 2023; Received in revised form 30 January 2024; Accepted 31 January 2024

Available online 8 February 2024

1600-6135/© 2024 The Authors. Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<sup>18</sup> Nephrology, Dialysis and Renal Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

<sup>19</sup> Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy

<sup>20</sup> Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria

---

## ABSTRACT

---

Membranous nephropathy (MN) is a leading cause of kidney failure worldwide and frequently recurs after transplant. Available data originated from small retrospective cohort studies or registry analyses; therefore, uncertainties remain on risk factors for MN recurrence and response to therapy. Within the Post-Transplant Glomerular Disease Consortium, we conducted a retrospective multicenter cohort study examining the MN recurrence rate, risk factors, and response to treatment. This study screened 22,921 patients across 3 continents and included 194 patients who underwent a kidney transplant due to biopsy-proven MN. The cumulative incidence of MN recurrence was 31% at 10 years posttransplant. Patients with a faster progression toward end-stage kidney disease were at higher risk of developing recurrent MN (hazard ratio [HR], 0.55 per decade; 95% confidence interval [CI], 0.35–0.88). Moreover, elevated pretransplant levels of anti-phospholipase A2 receptor (PLA2R) antibodies were strongly associated with recurrence (HR, 18.58; 95% CI, 5.37–64.27). Patients receiving rituximab for MN recurrence had a higher likelihood of achieving remission than patients receiving renin-angiotensin-aldosterone system inhibition alone. In sum, MN recurs in one-third of patients posttransplant, and measurement of serum anti-PLA2R antibody levels shortly before transplant could aid in risk-stratifying patients for MN recurrence. Moreover, patients receiving rituximab had a higher rate of treatment response.

---

## 1. Introduction

Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). While the short-term outcomes of kidney transplantation have significantly improved, long-term outcomes have only marginally improved over the past 30 years.<sup>1</sup> Excluding death as a cause of graft loss, recurrence of glomerular disease is the second leading cause of kidney graft loss.<sup>2–6</sup> Among the glomerular diseases that recur after transplantation, membranous nephropathy (MN) is one of the most common.<sup>7–11</sup> Therefore, investigating MN recurrence posttransplant is vital to improve the long-term outcomes of kidney transplant recipients.

MN is the leading cause of nephrotic syndrome in nondiabetic adults worldwide, frequently leading to ESKD.<sup>8,9</sup> The reported recurrence rate of MN following renal transplantation ranges from 6% to 55% (Supplementary Table 1). This considerable variation is likely attributed to the limited sample sizes of single-center studies and different criteria for the detection of recurrence, with centers performing protocol biopsies reporting higher rates.<sup>10–14</sup> MN recurrence has been associated with a higher risk of accelerated graft failure.<sup>15–17</sup> However, the recent identification of multiple autoantibodies against podocyte antigens has revolutionized the understanding and management of MN in native kidneys.<sup>18</sup> In particular, antibodies against phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain containing 7A (THSD7A) may be detectable in approximately 70% of all MN cases.<sup>19,20</sup> Treatment with B cell-depleting agents such as rituximab has changed the course of MN in native kidneys, leading to better responses and less toxicity,<sup>21</sup> but the impact of these discoveries in posttransplant recurrent MN remains to be determined.

We conducted a multicenter, international study on MN recurrence posttransplantation within the Post-Transplant Glomerular Disease (TANGO) Consortium. This collaborative effort between 39 transplant centers worldwide, spread across 5 continents, is dedicated to improving our understanding of glomerular disease posttransplant.<sup>22</sup> By utilizing retrospective clinical data and patient serum samples, we examined the incidence, associated risk factors, and treatment approaches of recurrent MN and evaluated subsequent graft outcomes.

## 2. Methods

### 2.1. Study design and endpoints

Sixteen transplant centers from the TANGO Consortium in Europe, North America, and South America participated in this retrospective cohort study. Our primary endpoint was the incidence of biopsy-proven MN recurrence after kidney transplantation in patients with a biopsy-proven diagnosis of primary MN in their native kidneys. Secondary endpoints included risk factors for MN recurrence, clinical outcomes, and response to treatment (complete, partial, or no remission).

A more detailed description can be found in the [Supplementary Methods](#).

### 2.2. Patient selection

Participating centers screened all patients who underwent a kidney transplant between January 2005 and December 2020, amounting to 22,921 transplant recipients.

A total of 208 patients were considered for the study and entered into a dedicated online database.<sup>22</sup> The study inclusion criteria

comprised adult patients who received a kidney transplant within the aforementioned timeframe and had biopsy-confirmed primary MN as the cause of their ESKD. Patients with a secondary cause of MN and those with de novo MN after transplantation were excluded.

In total, 194 adult patients ( $\geq 18$  years) met our inclusion criteria for primary analysis (Supplementary Fig. 1). Patients with a secondary cause of MN, death, or loss to follow-up immediately after transplant and/or patients with de novo MN were excluded. See Supplementary Figure 1 for further details.

In addition, patients from one Brazilian center without a native kidney biopsy due to advanced kidney disease at time of biopsy consideration were excluded from primary analysis. They were included in secondary analyses as they had biopsy-proven MN recurrence and pretransplant clinical course suggestive of MN.

The overall protocol of the TANGO Consortium was approved by the ethical committee of the Partners Human Research Committee at Massachusetts General Hospital in Boston (protocol number: 2015P000993) and adheres to the principles outlined in the Declaration of Helsinki. Additional information can be found in the Supplementary Methods.

### 2.3. Data and sample collection

Detailed deidentified health information was extracted from medical records. Patients were censored at the time of graft loss, patient death, loss to follow-up, or in December 2022. Patients were only classified as having recurrent MN if their recurrence was biopsy-proven. Clinical indication-guided biopsy was standard for most centers, whereas 2 centers performed protocol biopsies posttransplantation as part of routine care. Serum samples from included patients were retrospectively requested from participating transplant centers. These serum samples were required to be collected shortly before transplantation.

### 2.4. Antibody detection in sera

Serum PLA2R and THSD7A antibodies were detected using indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA). Serum PLA2R antibodies were assessed using both IIF and ELISA, whereas IIF was exclusively used to detect circulating THSD7A autoantibodies. Quantitation of positive anti-PLA2R sera was determined using the Euroimmun ELISA Kit. Positive and negative controls were extrapolated using the standard curve fit, positive  $\geq 20$  relative units (RU)/mL, borderline  $\geq 14$  to  $< 20$  RU/mL, and negative  $< 14$  RU/mL. See Supplemental Methods for further details.

### 2.5. Statistical analysis

Categorical variables are presented as frequencies and percentages, whereas continuous variables are presented as medians and interquartile ranges or means  $\pm$  standard deviations. Complete case analysis was used for statistical analysis of Table 1. *t* tests were used for continuous variables, whereas chi-

square or Fisher exact tests were used for binary and categorical variables, depending on group size.

Log-rank tests were used to compare 2 groups, whereas log-rank tests for trend were used for 3 or more groups. Missing data are shown in Supplementary Table 2 and were imputed using STATA's multiple imputation by chained equations procedure. See Supplementary Methods for more details. Univariable and multivariable Cox proportional hazards regression was performed with imputed data in Table 2, with categorical variables entered as binary variables. Schoenfeld residuals were evaluated to assess proportional hazard assumptions, and deviance residuals were used to evaluate model accuracy and outliers. Adverse events after kidney transplantation (acute rejection, cytomegalovirus [CMV], cancer, and BK viremia) were treated as time-varying covariates to assess the association between their occurrence and subsequent development of recurrent MN. Prism 9.4.1 (GraphPad) and STATA (version 17.0, StataCorp LLC) were employed to carry out statistical analysis and generate graphics.

## 3. Results

### 3.1. Cohort demographics

Our overall cohort included 194 transplant recipients with biopsy-proven primary MN in their native kidneys. Most patients were White (72%). Approximately 16% of patients underwent a pre-emptive transplant, and 37% received a transplant from a living donor. Basiliximab was the most commonly used induction therapy (42%) along with triple maintenance immunosuppression consisting of tacrolimus, mycophenolate, and steroids (70%). Additionally, 16% of the patients were on an early steroid withdrawal regimen. One center used alemtuzumab induction with tacrolimus maintenance monotherapy and short-course steroids for most of their patients. Additional information about the cohort demographics can be found in Table 1.

### 3.2. Incidence of MN recurrence after kidney transplantation

During a median follow-up period of 5.9 years (interquartile range [IQR], 3.2–8.6 years), 43 patients experienced recurrent MN. The prevalence of MN recurrence increased gradually after transplant (Fig. 1), with a cumulative incidence of 31% at 10 years (95% CI, 23–41) posttransplantation. The median time to recurrence was 1.9 years (IQR, 0.4–4.3), with 7% ( $n = 4$ ) of recurrences diagnosed on protocol biopsy and 93% ( $n = 39$ ) detected on a clinically indicated biopsy. The 10-year cumulative incidence rate of MN recurrence per continent is shown in Supplementary Figure 2.

Patients who experienced MN recurrence were younger at the time of primary MN diagnosis in their native kidneys (36 years vs 46 years,  $P = .02$ , Wilcoxon rank sum test) and had a shorter time from MN diagnosis to ESKD (65 months vs 116 months,  $P = .02$ , Wilcoxon rank sum test). No differences were observed when comparing tacrolimus trough levels posttransplant according to remission rates in patients with recurrent MN (Supplementary Fig. 3).

**Table 1**

Baseline characteristics of recipients and donors in all patients and according to MN recurrence.

Characteristic	Overall cohort (n = 194)	No recurrence (n = 151)	Recurrence (n = 43)
Follow-up, y	5.9 [3.2-8.6]	5.1 [3.2-8.2]	7.1 [3.3-10.4]
Age at transplantation, y	54 [43-64]	52 [41-64]	56 [48-64]
Age at diagnosis, y	37 [26-51]	36 [24-48]	46 [33-53]
Male sex	142 (73)	109 (72)	33 (77)
<b>Race</b>			
Asian	5 (3)	5 (3)	0 (0)
Black	13 (7)	11 (7)	2 (5)
White	139 (72)	106 (70)	33 (77)
Mixed	5 (3)	4 (3)	1 (2)
BMI at transplantation	25.4 [22.5-29.2]	25.1 [22.1-29.2]	26.3 [24.3-29.1]
Time from diagnosis to ESKD, mo	95 [44-213]	116 [51-225]	65 [37-122]
Time on dialysis, mo	29 [14-60]	29 [14-59]	26 [14-60]
<b>Type of dialysis</b>			
Hemodialysis	133 (69)	99 (67)	34 (79)
Peritoneal dialysis	17 (9)	16 (11)	1 (2)
Both	11 (6)	11 (7)	0 (0)
None (pre-emptive transplant)	33 (16)	23 (15)	8 (19)
<b>Number of prior transplants</b>			
None	167 (86)	129 (85)	38 (88)
One or more transplant	27 (14)	22 (15)	5 (12)
DSA at time of transplant	14 (7)	13 (9)	1 (2)
Deceased donor	121 (62)	94 (62)	27 (63)
Extended criteria donor (KDPI >85%)	40 (33)	34 (36)	6 (22)
Cold ischemia time, h	17 ± 8	17 ± 8	16 ± 7
Living donor	73 (38)	57 (38)	16 (37)
Living related donor	37 (51)	27 (47)	10 (63)
Donor age, y	52 [42-61]	52 [42-61]	55 [43-61]
HLA-A/B/DR mismatch	3 [2-5]	3 [2-5]	3 [3-4]
<b>Induction therapy</b>			
None	14 (7)	9 (6)	5 (11)
Basiliximab	83 (42)	60 (40)	15 (35)
Anti-thymocyte globulin	75 (39)	64 (42)	19 (44)
Alemtuzumab	17 (9)	13 (9)	4 (9)
Daclizumab	5 (3)	5 (3)	0 (0)
<b>Baseline immunosuppressive regimen</b>			
Tacrolimus + MMF + steroids	135 (70)	110 (73)	25 (58)
Cyclosporine + MMF + steroids	12 (6)	9 (6)	3 (7)
Tacrolimus + MMF	19 (10)	12 (8)	7 (16)
Tacrolimus	16 (8)	13 (9)	3 (7)

(continued on next page)

**Table 1** (continued)

Characteristic	Overall cohort (n = 194)	No recurrence (n = 151)	Recurrence (n = 43)
Other	8 (4)	5 (3)	3 (7)
Steroid free/early steroid withdrawal	29 (16)	22 (15)	7 (17)

Values represent frequency (percentage), mean ± standard deviation (SD), or median [interquartile range].

MN, membranous nephropathy; BMI, body mass index; ESKD, end-stage kidney disease; DSA, donor-specific antibodies; KPDI, kidney donor profile index; HLA, human leukocyte antigen, MMF, mycophenolate mofetil.

**Table 2**

Associations of clinical characteristics with recurrence of MN. Values represent frequency (percentage) unless otherwise stated. Significant values are shown in bold.

Variable	Missing values (%)	Total number of events	Unadjusted analysis hazard ratio (95% CI)	Multivariable analysis hazard ratio (95% CI)	P value Multivariable analysis
<b>Geographic location</b>					
North America	0 (0)	13	Ref	Ref	
Europe	0 (0)	23	0.84 (0.46-1.54)	0.70 (0.36-1.39)	0.31
Brazil	0 (0)	7	0.81 (0.36-1.82)	0.64 (0.25-1.60)	0.34
BMI	12 (6)	41	1.02 (0.96-1.08)	1.01 (0.95-1.08)	0.71
Time from diagnosis to ESKD, per 10 y	24 (12)	40	<b>0.64 (0.43-0.94)</b>	<b>0.55 (0.35-0.88)</b>	<b>0.013</b>
HLA-mismatch	11 (6)	41	1.02 (0.84-1.23)	1.04 (0.85-1.28)	0.68
Living Tx	0 (0)	16	0.84 (0.45-1.57)	0.83 (0.41-1.70)	0.61
Age of donor, per 10 y	25 (13)	37	1.10 (0.87-1.39)	1.17 (0.90-1.52)	0.23
Pre-emptive transplant	0 (0)	8	1.16 (0.54-2.51)	1.92 (0.78-4.68)	0.15
Use of induction	0 (0)	38	0.71 (0.28-1.82)	0.84 (0.31-2.29)	0.73
History of prior kidney Tx	0 (0)	5	0.81 (0.32-2.06)	1.70 (0.58-4.68)	0.33
Immunosuppression with CNI + MMF + steroids	1 (1)	43	0.55 (0.29-1.03)	0.60 (0.30-1.19)	0.14

MN, membranous nephropathy; CI, confidence interval; Ref, reference; BMI, body mass index; ESKD, end-stage kidney disease; HLA, human leukocyte antigen; Tx, transplant; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.


**3.3. Identification of risk factors for MN recurrence**

Both univariable and multivariable Cox regression analyses were performed to identify potential risk factors based on patients’ characteristics (Table 2). Univariable analysis revealed

that patients who had a faster progression toward ESKD were at a higher risk of developing recurrent MN. This remained significant in the multivariable model after adjusting for confounding factors, with a HR of 0.55 per decade (95% CI, 0.35-0.88). The geographical location (Europe, North America, or South America) of the patient was not associated with recurrence (Table 2). Additionally, neither body mass index, human leukocyte antigen mismatch, whether the kidney transplant came from a living donor, donor age, pre-emptive transplantation, use of induction immunosuppression, history of a prior kidney transplant, nor use of a triple immunosuppressive regimen consisting of calcineurin inhibitors, mycophenolate mofetil, and steroids was correlated with MN recurrence.

**3.4. Circulating anti-podocyte antibodies and MN recurrence**

Antibodies against PLA2R and THSD7A frequently cause MN, though they are not universally tested prior to transplantation.<sup>23</sup> Among the 194 patients in our cohort, 9 were screened for pretransplant anti-PLA2R antibodies at their transplant center, whereas none were screened for anti-THSD7A



**Figure 1.** Cumulative incidence of MN recurrence posttransplantation. Error bands represent 95% CI. CI, confidence interval; MN, membranous nephropathy.

antibodies. Therefore, we systemically assessed for the presence of these antibodies in pretransplant sera of 46 patients with available samples. Using IIF and ELISA, anti-PLA2R antibodies were confirmed in pretransplant sera from 19 patients. The remaining 27 tested negative for anti-PLA2R antibodies. To resolve borderline anti-PLA2R ELISA values for binary analyses, we utilized IIF to categorize patients into with or without antibodies against PLA2R (Supplementary Fig. 4). For quantification of anti-THSD7A antibodies, collected serum samples were assessed through IIF. All 46 patients tested negative for anti-THSD7A antibodies.

We combined the data from 9 patients with available pretransplant anti-PLA2R titers, along with those patients ( $n = 46$ ) for whom pretransplant sera was accessible, resulting in a total of 55 patients for assessment of anti-PLA2R antibodies. Sera were collected with a median of 3 days prior to transplant (IQR, 0-46 days). In univariable Cox regression analysis, the presence of anti-PLA2R antibodies shortly before transplant was strongly associated with recurrence (HR, 18.58; 95% CI, 5.37-64.27). The overall sensitivity and specificity of pretransplant anti-PLA2R antibodies for predicting recurrence were 0.85 (95% CI, 0.76-0.94) and 0.91 (95% CI, 0.84-0.99), respectively.

Subsequently, we performed quantitative analysis of ELISA results and compared anti-PLA2R antibody levels of patients with ( $n = 20$ ) and without ( $n = 35$ ) MN recurrence (Fig. 2). Of the 20 patients with recurrence, 17 tested positive for anti-PLA2R antibodies prior to transplant. Among the 35 patients without recurrence, only 3 tested positive for anti-PLA2R antibodies prior to transplant. Higher pretransplant anti-PLA2R antibody values were associated with recurrence of MN ( $P < .0001$ , Wilcoxon rank sum test). In addition, when we categorized patients based on their pretransplant antibody status, those with confirmed positive pretransplant anti-PLA2R antibodies were more likely to develop MN recurrence ( $P < .0001$ , Wilcoxon rank sum test), as depicted in Figure 3A. Patients with confirmed pretransplant antibodies against PLA2R were further stratified into 2 groups based on their quantitative anti-PLA2R ELISA values, using a cutoff of 150 RU/mL (Fig. 3B).<sup>24</sup> Patients with a high titer had earlier MN recurrence (median time to recurrence 0.57 years; IQR, 0.38-0.89), compared with those with a titer  $<150$  RU/mL (median time to recurrence 1.78 years; IQR, 1.01-4.79).

Overall, patients with serum anti-PLA2R antibodies shortly before transplant were more likely to develop recurrence, with high pretransplant titer levels being associated with developing recurrence more frequently and earlier after transplant.

### 3.5. Graft failure and recurrence

During the follow-up period, allograft failure was comparable between patients with and without recurrent MN, with 9% of patients experiencing allograft failure in each group (4 and 13 patients, respectively). The 10-year graft survival rate was 87% in the recurrent group compared with 90% in the nonrecurrent group. Kaplan-Meier graft survival, conducted on patients with recurrent MN after the confirmation of recurrence, showed a 6-year graft survival rate of 89%.

In patients with recurrent MN, graft failure was mainly attributed to MN recurrence ( $n = 3$ ) and infection ( $n = 1$ ). In patients without recurrence, allograft failure was caused by rejection ( $n = 7$ ), followed by chronic allograft nephropathy ( $n = 2$ ), unknown causes ( $n = 2$ ), infection ( $n = 1$ ), or urological complications ( $n = 1$ ).

In patients with recurrent MN, patients who achieved complete or partial remission showed a favorable trend toward better graft survival rates compared with those who did not (see Supplemental Fig. 5).

In the recurrent group, 6 patients (14%) died, compared with 16 patients (11%) in the nonrecurrent group. Of the 27 patients who had received a prior kidney transplant, 6 lost their prior kidney allograft due to recurrent MN. Of the 6 patients who experienced allograft loss due to recurrence, 3 had recurrence again in their subsequent allograft.


### 3.6. MN recurrence and complications after transplantation

We investigated whether patients with recurrent MN were more prone to posttransplant complications, such as acute rejection, CMV infection, BK viremia, posttransplant diabetes mellitus, cancer, and cardiovascular disease, given their increased use of immunosuppressive drugs and the risk of adverse events associated with nephrotic syndrome. Cox regression analyses were performed for acute rejection, CMV infection, BK viremia, and cancer, whereas linear regression analysis was used to assess any association with posttransplant diabetes and cardiovascular disease. We adjusted for several confounders, including pretransplant donor-specific antibody and pre-emptive kidney transplant for patients with acute rejection and recipient/donor CMV IgG status for those with CMV infection. Our findings showed no difference in association between MN recurrence and the incidence of adverse events (Table 3).

### 3.7. Response to treatment of recurrent MN

We evaluated the treatment regimen and response in 51 patients with MN posttransplantation: 43 patients of the general cohort and 8 patients from the Brazilian center without native kidney biopsies due to advanced kidney disease at time of biopsy consideration (refer to Methods). Although treatments varied, the majority of patients received RAAS (renin-angiotensin-aldosterone system) inhibitors and/or rituximab.

Among the 51 patients with posttransplant MN, 25 received rituximab, either with or without additional RAAS inhibition. Eighteen patients were treated with RAAS inhibition alone. The remaining 8 patients received either spironolactone ( $n = 3$ ), RAAS inhibition in combination with immunosuppressants other than rituximab ( $n = 2$ ), or did not receive any additional treatment ( $n = 3$ ) (Fig. 4). Rituximab with or without RAAS inhibition was associated with partial or complete remission in 17 patients (68%), whereas RAAS inhibition alone led to partial or complete remission in 6 patients (33%).




**Figure 2.** Quantitative ELISA results of anti-PLA2R antibodies between the nonrecurrent and recurrent group. Titer results reported as single values, including median and IQR. Wilcoxon rank sum test was used for comparison analysis. Ab, antibody; ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; MN, membranous nephropathy; PLA2R, phospholipase A2 receptor; RU, relative unit.

**4. Discussion**


In this large multicenter retrospective cohort study, designed to investigate MN recurrence using clinical data and serum samples, the cumulative incidence of recurrent MN was 31% at 10 years posttransplant. Faster progression toward ESKD in the native kidneys was associated with a higher risk of developing recurrent MN. Moreover, the presence of pretransplant serum antibodies against PLA2R was strongly associated with

recurrence. Patients with MN recurrence receiving rituximab exhibited improved remission rates compared with patients with solely RAAS inhibition, resulting in minimal impact on medium-term graft survival.

The recurrence rate of MN following kidney transplantation has been variable across studies, ranging from 6% to 55%, reflective of limited sample sizes of single-center studies and different criteria for the detection of recurrence such as in centers performing protocol biopsies.<sup>10-15,25-32</sup> Studies using registry



**Figure 3.** Cumulative incidence curve of recurrent MN stratified by pretransplant anti-PLA2R antibody status and levels. (A) Cumulative incidence of recurrent MN stratified by either negative or positive pretransplant anti-PLA2R results. (B) Cumulative incidence of recurrent MN stratified by level of pretransplant anti-PLA2R antibodies (higher or lower than 150 RU/mL). Log-rank test was used for comparison analysis. Ab, antibody; MN, membranous nephropathy; PLA2R, phospholipase A2 receptor; RU, relative unit.



**Table 3**  
Associations of posttransplantation time-dependent adverse events with recurrent MN.

Adverse event	Overall cohort (n = 194)	No recurrence (n = 151)	Recurrence (n = 43)	Hazard ratio (95% CI)
Acute rejection <sup>a</sup>	43 (22)	35 (23)	8 (19)	0.86 (0.39-1.88)
Cellular mediated	34 (18)	27 (18)	7 (16)	
Antibody mediated	6 (3)	6 (4)	0 (0)	
Mixed	3 (2)	2 (1)	1 (2)	
CMV viremia <sup>b</sup>	19 (10)	15(10)	4(9)	0.70 (0.22-2.20)
BK viremia	20 (11)	14(10)	6(15)	1.55 (0.59-4.03)
Cancer	31 (15)	22 (15)	9 (21)	1.26 (0.58-2.75)
New-onset DM	40 (21)	32 (21)	8 (19)	OR: 0.84 (0.36-2.00)
CAD	10 (5)	8 (5)	2 (5)	OR: 0.87 (0.18-4.24)
Heart failure	7 (4)	4 (3)	3 (7)	OR: 2.74 (0.59-12.73)

Values represent frequency (percentage) unless otherwise stated.

Acute rejection, CMV, BK viremia, and cancer were assessed by Cox regression. New-onset DM, CAD, and heart failure were analyzed by logistic regression. MN, membranous nephropathy; CI, confidence interval; CMV, cytomegalovirus; DM, diabetes mellitus; OR, odds ratio; CAD, coronary artery disease.

<sup>a</sup> Hazard ratio is corrected for pretransplant DSA and pre-emptive kidney transplant.


<sup>b</sup> Hazard ratio is corrected for pretransplant recipient/donor CMV IgG status.

data often fail to capture cases of MN recurrence that did not lead to graft loss, represented by a lower reported recurrence rate.<sup>3,13</sup> Conversely, studies from centers performing protocol biopsies reported higher incidence rates.<sup>11,12</sup> To increase the sample size, we collaborated with multiple transplant centers worldwide, ensuring representation of diverse ethnicities and immunosuppression regimens. Moreover, the contemporary data collection reflects the more recent understanding of MN pathogenesis as primarily mediated by autoantibodies against podocyte proteins while also highlighting the impact of rituximab use on MN outcomes, as it has become the immunosuppressive treatment of choice.

Among risk factors for MN recurrence, few patient demographics have been found to be consistently associated with recurrent MN (Supplementary Table 1). Of these, high levels of proteinuria pretransplant, shorter waitlist times, being of White

race, older age at the time of transplant, and steroid-free immunosuppressive regimens were identified as potential predictors for recurrence.<sup>11,31,32</sup> We found that MN recurrence was associated with a shorter duration between diagnosis of native kidney disease and ESKD. This finding is consistent with reports of other glomerular diseases, such as IgA nephropathy and focal segmental glomerulosclerosis, in which a more aggressive native disease course is associated with an increased risk of recurrence after transplantation.<sup>33,34</sup>

The identification of autoantibodies against podocytes was a major revolution in the understanding of the pathogenesis of MN in native kidneys. Indeed, the detection of autoantibodies against the podocyte antigen PLA2R has been used for the diagnosis of MN as well as to monitor response to therapy and predict relapses in patients with native MN.<sup>19,35-38</sup> In these patients, the presence of anti-PLA2R antibodies is associated with the



**Figure 4.** Initiated treatment regimens in patients with MN posttransplantation. MN, membranous nephropathy; RAAS, renin-angiotensin-aldosterone system. This figure was created with BioRender.com.



development of MN months to years before clinical disease, and trends in anti-PLA2R antibody titers correlate with proteinuria. However, reports describing the use of anti-PLA2R antibody measurement pre- and posttransplant are more limited, with only few small studies indicating that it could aid in the prediction and detection of recurrence.<sup>11,30,39</sup> Our results support and expand these initial findings, as they indicate a strong correlation between the presence of serum anti-PLA2R antibodies prior to transplant and MN recurrence posttransplant. Furthermore, our findings highlight the importance of anti-PLA2R antibody levels, as patients with high levels (>150 RU/mL) shortly before transplantation are prone to earlier recurrence, suggesting that titers can be used to stratify the risk of recurrence. Our cutoff of 150 RU/mL is aligned with the 2021 Kidney Disease: Improving Global Outcomes guidelines, which state that an anti-PLA2R antibody level above 150 RU/mL is suggested as a clinical criterion for a high risk of progressive kidney function loss in MN in native kidney disease.<sup>24</sup> In sum, our data support the utility of measuring serum anti-PLA2R antibody levels in MN patients on the transplant waitlist to establish baseline values. In patients with highly elevated pretransplant serum anti-PLA2R antibody titers, further studies are needed to define if a pre-emptive B cell depletion approach is warranted or closer surveillance with early treatment is recommended to minimize the potential impact of MN recurrence.<sup>12</sup>

In recent years, multiple other antibody targets have been identified in MN including THSD7A, neural epidermal growth factor-like 1 protein, and semaphorin 3B, among others.<sup>40–50</sup> The role of different autoantibodies in MN recurrence has not been systemically assessed posttransplantation. Our study provided an initial picture of the dominance of anti-PLA2R antibodies compared to anti-THSD7A antibodies in MN recurrence. Nonetheless, a larger study assessing all potential autoantibodies previously identified as drivers of MN is needed for a more detailed understanding of their role in MN recurrence.

The management of MN recurrence is largely empirical and draws heavily from clinical trials conducted for primary MN patients. Most patients with MN recurrence in our study received RAAS inhibition. Notably, those who were treated with rituximab exhibited a higher rate of proteinuria remission, supporting the use of this treatment approach for patients with MN recurrence, regardless of their clinical phenotype. Studies conducted prior to the identification of serum anti-podocyte antibodies and before the introduction of rituximab therapy demonstrated the notable influence of posttransplant MN on graft survival.<sup>15–17</sup> In our study, which included patients transplanted from 2005 onwards, most participants received RAAS inhibitors and/or rituximab, and we observed high remission rates after administration of rituximab. This is likely the reason why MN recurrence did not impact graft survival in our study.

Certain limitations should be considered when interpreting our data. Despite having one of the largest cohorts to date (Supplementary Table 1), our sample size is still relatively small, which may affect the statistical power of our analysis. Furthermore, the retrospective design of the study presents inherent limitations, including the possibility of selection bias, as patients were not

randomly assigned to treatment groups. The imputation of missing data and adjustment of confounders could also introduce bias. Additionally, as only 2 centers performed protocol biopsies, it may be that not all patients with MN recurrence were captured. Lastly, the absence of kidney biopsy PLA2R immunohistochemistry staining could introduce underreporting bias in assessing the correlation between anti-PLA2R antibodies and recurrence. These caveats should be taken into consideration when interpreting our findings, and future studies should aim to address these limitations to improve the reliability of the results. Nonetheless, our study provides a multicenter, real-life picture of MN recurrence, including management and outcomes.

In summary, MN recurs in approximately one-third of transplant patients. The presence of serum anti-PLA2R antibodies before transplant are highly predictive of recurrence, underscoring the need for close monitoring and tailored therapeutic interventions for MN transplant candidates. Patients with MN recurrence receiving rituximab have a high rate of treatment response, with minimal impact on medium-term graft survival.

## Acknowledgments

This work was conducted with support from UM1TR004408 award through Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University, and its affiliated academic healthcare centers, or the National Institutes of Health.

## Funding

This study was supported in part by the Harold and Ellen Danser Endowed/Distinguished Chair in Transplantation at Massachusetts General Hospital, Boston, Massachusetts.

## Declaration of competing interest

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Helio Tedesco Silva is supported by research grants from Novartis, Natera, and Merck & Co. through his institution. He received honoraria for lectures from Takeda, EMS, CardEx and Natera. Additionally, he received monetary support from Takeda to attend meetings. A. Bernard Collins receives royalties from Elsevier. He also reports receiving honoraria from Euroimmun. Nikhil Agrawal has employment stocks and options from CareDx Inc. He is also currently employed by CareDx Inc. Ayman Al Jurdi is supported by AstraZeneca through grant funding for an investigator-initiated study related to another project. Roberto C. Manfro served on the data safety monitoring board of Instituto Butantan in São Paulo, Brazil, for which he did not receive any payments. Giorgia Comai received honoraria from Novartis, Hansa Biopharma, and Alexion. Additionally, she is a part of the

Biotest Advisory Board, for which she receives payments. Paolo Cravedi is supported by the NIH award R01 DK123234 and has received research funding from Chinook Therapeutics. Leonardo V. Riella is supported by the NIH award R01 AI143887 and has received research funding for unrelated projects from Visterra, Caredx, AstraZeneca, Natera, and Bristol-Meyers-Squibb. All remaining authors have nothing to disclose.

## Data availability

The data that support the findings of this study are available from the corresponding author on reasonable request.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ajt.2024.01.036>.

## ORCID

Frank Hullekes <https://orcid.org/0000-0002-2260-7175>  
 Audrey Uffing <https://orcid.org/0000-0001-6108-9828>  
 Rucháma Verhoeff <https://orcid.org/0000-0003-2220-0540>  
 Harald Seeger <https://orcid.org/0000-0003-1552-7983>  
 Juliana Mansur <https://orcid.org/0000-0002-0820-5815>  
 Gianna Mastroianni-Kirsztajn <https://orcid.org/0000-0003-1317-4109>  
 Anna Buxeda <https://orcid.org/0000-0001-7305-3259>  
 Carlos Arias-Cabrales <https://orcid.org/0000-0002-1729-8152>  
 Leela Moren a <https://orcid.org/0000-0001-8295-1026>  
 Andreas Kousios <https://orcid.org/0000-0003-0042-1836>  
 Paolo Malvezzi <https://orcid.org/0000-0002-8549-5561>  
 Pitchaphon Nissaisorakarn <https://orcid.org/0000-0002-0245-2954>  
 Ayman Al Jurdi <https://orcid.org/0000-0002-7957-137X>  
 Enver Akalin <https://orcid.org/0000-0003-1341-5144>  
 Fabiana Agena <https://orcid.org/0000-0002-4526-4857>  
 Carlucci Ventura <https://orcid.org/0000-0001-8398-1745>  
 Roberto C. Manfro <https://orcid.org/0000-0001-8324-3734>  
 Andrea Carla Bauer <https://orcid.org/0000-0002-5041-4792>  
 Marilda Mazzali <https://orcid.org/0000-0001-6297-4909>  
 Gaetano La Manna <https://orcid.org/0000-0001-5473-8551>  
 Claudia Bini <https://orcid.org/0000-0003-2617-4060>  
 Giorgia Comai <https://orcid.org/0000-0003-4160-8840>  
 Roman Reindl-Schwaighofer <https://orcid.org/0000-0002-4419-6282>  
 Stefan Berger <https://orcid.org/0000-0003-2228-4676>  
 Paolo Cravedi <https://orcid.org/0000-0001-7837-0923>  
 Leonardo V. Riella <https://orcid.org/0000-0002-7636-3196>

## References

- Coemans M, S usal C, D ohler B, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. *Kidney Int.* 2018;94(5):964–973. <https://doi.org/10.1016/j.kint.2018.05.018>.
- Uffing A, P erez-S aez MJ, Mazzali M, et al. Recurrence of FSGS after kidney transplantation in adults. *Clin J Am Soc Nephrol.* 2020;15(2):247–256. <https://doi.org/10.2215/cjn.08970719>.
- Allen PJ, Chadban SJ, Craig JC, et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. *Kidney Int.* 2017;92(2):461–469. <https://doi.org/10.1016/j.kint.2017.03.015>.
- O’Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC. Kidney transplantation outcomes across GN subtypes in the United States. *J Am Soc Nephrol.* 2017;28(2):632–644. <https://doi.org/10.1681/asn.2016020126>.
- Pippias M, Stel VS, Arest e-Fosalba N, et al. Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry. *Transplantation.* 2016;100(9):1955–1962. <https://doi.org/10.1097/tp.0000000000000962>.
- Uffing A, Hullekes F, Riella LV, Hogan JJ. Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas. *Clin J Am Soc Nephrol.* 2021;16(11):1730–1742. <https://doi.org/10.2215/cjn.00280121>.
- Leon J, P erez-S aez MJ, Batal I, et al. Membranous nephropathy posttransplantation: an update of the pathophysiology and management. *Transplantation.* 2019;103(10):1990–2002. <https://doi.org/10.1097/tp.0000000000002758>.
- McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. *Nephrol Dial Transplant.* 2011;26(2):414–430. <https://doi.org/10.1093/ndt/gfq665>.
- Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. *Am J Kidney Dis.* 2000;35(1):157–165. [https://doi.org/10.1016/s0272-6386\(00\)70316-7](https://doi.org/10.1016/s0272-6386(00)70316-7).
- Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. *N Engl J Med.* 2002;347(2):103–109. <https://doi.org/10.1056/NEJMoa013036>.
- Grupper A, Cornell LD, Fervenza FC, Beck Jr LH, Lorenz E, Cosio FG. Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications. *Transplantation.* 2016;100(12):2710–2716. <https://doi.org/10.1097/tp.0000000000001056>.
- Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. *Kidney Int.* 2017;91(2):304–314. <https://doi.org/10.1016/j.kint.2016.08.030>.
- Yang WL, Bose B, Zhang L, et al. Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: a cohort study using the Australia and New Zealand Dialysis and Transplant Registry. *PLoS One.* 2019;14(8):e0221531. <https://doi.org/10.1371/journal.pone.0221531>.
- Chung EYM, Blazek K, Teixeira-Pinto A, et al. Predictive models for recurrent membranous nephropathy after kidney transplantation. *Transplant Direct.* 2022;8(9):e1357. <https://doi.org/10.1097/txd.0000000000001357>.
- Dabade TS, Grande JP, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. *Am J Transplant.* 2008;8(6):1318–1322. <https://doi.org/10.1111/j.1600-6143.2008.02237.x>.
- Rodr guez EF, Cosio FG, Nasr SH, et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. *Am J Transplant.* 2012;12(4):1029–1038. <https://doi.org/10.1111/j.1600-6143.2011.03903.x>.
- Jiang SH, Kennard AL, Walters GD. Recurrent glomerulonephritis following renal transplantation and impact on graft survival. *BMC Nephrol.* 2018;19(1):344. <https://doi.org/10.1186/s12882-018-1135-7>.
- Sethi S. New ‘antigens’ in membranous nephropathy. *J Am Soc Nephrol.* 2021;32(2):268–278. <https://doi.org/10.1681/asn.2020071082>.
- Beck Jr LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med.* 2009;361(1):11–21. <https://doi.org/10.1056/NEJMoa0810457>.
- Tomas NM, Beck Jr LH, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. *N Engl J Med.* 2014;371(24):2277–2287. <https://doi.org/10.1056/NEJMoa1409354>.
- Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. *N Engl J Med.* 2019;381(1):36–46. <https://doi.org/10.1056/NEJMoa1814427>.
- Uffing A, P erez-S aez MJ, La Manna G, et al. A large, international study on post-transplant glomerular diseases: the TANGO project. *BMC Nephrol.* 2018;19(1):229. <https://doi.org/10.1186/s12882-018-1025-z>.

23. Hogan JJ, Zee J, Beck LH. Towards optimizing use of PLA2R antibody testing in membranous nephropathy. *J Nephrol*. 2021;34(2):557–559. <https://doi.org/10.1007/s40620-021-00971-w>.
24. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int*. 2021;100(4S):S1–S276. <https://doi.org/10.1016/j.kint.2021.05.021>.
25. Chailimpamontree W, Dmitrienko S, Li G, et al. Probability, predictors, and prognosis of posttransplantation glomerulonephritis. *J Am Soc Nephrol*. 2009;20(4):843–851. <https://doi.org/10.1681/asn.2008050454>.
26. El-Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. *Am J Transplant*. 2009;9(12):2800–2807. <https://doi.org/10.1111/j.1600-6143.2009.02851.x>.
27. Moroni G, Gallelli B, Quagliani S, et al. Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN). *Nephrol Dial Transplant*. 2010;25(10):3408–3415. <https://doi.org/10.1093/ndt/gfq223>.
28. Sprangers B, Lefkowitz GI, Cohen SD, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. *Clin J Am Soc Nephrol*. 2010;5(5):790–797. <https://doi.org/10.2215/cjn.04120609>.
29. Seitz-Polski B, Payré C, Ambrosetti D, et al. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. *Nephrol Dial Transplant*. 2014;29(12):2334–2342. <https://doi.org/10.1093/ndt/gfu252>.
30. Quintana LF, Blasco M, Seras M, et al. Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy. *Transplantation*. 2015;99(8):1709–1714. <https://doi.org/10.1097/tp.0000000000000630>.
31. Gupta G, Fattah H, Ayalon R, et al. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. *Clin Transplant*. 2016;30(4):461–469. <https://doi.org/10.1111/ctr.12711>.
32. Batal I, Vasilescu ER, Dadhania DM, et al. Association of HLA typing and alloimmunity with posttransplantation membranous nephropathy: a multicenter case series. *Am J Kidney Dis*. 2020;76(3):374–383. <https://doi.org/10.1053/j.ajkd.2020.01.009>.
33. Avasare RS, Rosenstiel PE, Zaky ZS, et al. Predicting post-transplant recurrence of IgA nephropathy: the importance of crescents. *Am J Nephrol*. 2017;45(2):99–106. <https://doi.org/10.1159/000453081>.
34. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. *J Am Soc Nephrol*. 1992;2(12 Suppl):S258–S263. <https://doi.org/10.1681/ASN.V212s258>.
35. Seitz-Polski B, Debiec H, Rousseau A, et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. *J Am Soc Nephrol*. 2018;29(2):401–408. <https://doi.org/10.1681/asn.2017070734>.
36. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. *J Am Soc Nephrol*. 2014;25(6):1357–1366. <https://doi.org/10.1681/asn.2013040430>.
37. Burbelo PD, Joshi M, Chaturvedi A, et al. Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. *J Am Soc Nephrol*. 2020;31(1):208–217. <https://doi.org/10.1681/asn.2019050538>.
38. Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. *Kidney Int*. 2019;95(2):429–438. <https://doi.org/10.1016/j.kint.2018.10.021>.
39. Kattah A, Ayalon R, Beck Jr LH, et al. Anti-phospholipase A<sub>2</sub> receptor antibodies in recurrent membranous nephropathy. *Am J Transplant*. 2015;15(5):1349–1359. <https://doi.org/10.1111/ajt.13133>.
40. Solà-Porta E, Buxeda A, Lop J, et al. THSD7A-positive membranous nephropathy after kidney transplantation: a case report. *Nefrologia (Engl Ed)*. 2023. <https://doi.org/10.1016/j.nefro.2022.09.005>. Published online January 19.
41. Fila M, Debiec H, Perrochia H, et al. Recurrence of anti-semaphorin 3B-mediated membranous nephropathy after kidney transplantation. *J Am Soc Nephrol*. 2022;33(3):503–509. <https://doi.org/10.1681/asn.2021101323>.
42. Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. *Kidney Int*. 2020;97(1):163–174. <https://doi.org/10.1016/j.kint.2019.09.014>.
43. Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/exostosin 2-associated membranous nephropathy. *J Am Soc Nephrol*. 2019;30(6):1123–1136. <https://doi.org/10.1681/asn.2018080852>.
44. Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. *Kidney Int*. 2020;98(5):1253–1264. <https://doi.org/10.1016/j.kint.2020.05.030>.
45. Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy. *J Am Soc Nephrol*. 2021;32(5):1249–1261. <https://doi.org/10.1681/asn.2020081165>.
46. Sethi S, Madden B, Casal Moura M, et al. Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1. *J Am Soc Nephrol*. 2022;33(5):1033–1044. <https://doi.org/10.1681/asn.2021111488>.
47. Sethi S, Madden B, Casal Moura M, et al. Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor. *J Am Soc Nephrol*. 2023;34(3):374–384. <https://doi.org/10.1681/asn.0000000000000061>.
48. Le Quintrec M, Teisseyre M, Bec N, et al. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. *Kidney Int*. 2021;100(6):1240–1249. <https://doi.org/10.1016/j.kint.2021.08.014>.
49. Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. *Kidney Int*. 2021;100(1):171–181. <https://doi.org/10.1016/j.kint.2020.09.016>.
50. Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy. *J Am Soc Nephrol*. 2021;32(7):1666–1681. <https://doi.org/10.1681/asn.2020101395>.